Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
<p>Abstract</p> <p>Background</p> <p>The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and 4-hydroxy-<it>N</it&g...
Main Authors: | Lundgren Steinar, Geisler Jürgen, Gjerde Jennifer, Ekse Dagfinn, Varhaug Jan, Mellgren Gunnar, Steen Vidar M, Lien Ernst A |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-06-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/313 |
Similar Items
-
Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
by: Moi Line L, et al.
Published: (2012-06-01) -
Tamoxifen non-estrogen receptor mediated molecular targets
by: Tatiana Bogush, et al.
Published: (2012-10-01) -
A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen
by: Renée de Leeuw, et al.
Published: (2011-01-01) -
Prospects for the use of selective estrogen receptor modulator tamoxifen
Published: (2012-03-01) -
Genotoxicity of tamoxifen and structural analogues of tamoxifen : studies on the activation of tamoxifen by cytochrome P450s and peroxidase
by: Davies, Adrian M.
Published: (1999)